Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26.2;q22) is commonly a therapy-related disease associated with poor outcome

American Journal of Clinical Pathology

Volumn 138, Issue 1, 2012, Pages 146-152

  Li, Shaoying ^a   Yin, C Cameron ^a   Medeiros, L Jeffrey ^a   Bueso Ramos, Carlos ^a   Lu, Gary ^a   Lin, Pei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; inv(3) t(3; 3); Myelodysplastic syndrome; t(3; 21)(q26.2; q22); Therapy related MDS AML

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOGUAZONE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; PROCARBAZINE; RETINOIC ACID; RITUXIMAB; TAMOXIFEN; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW BIOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CHROMOSOME 3Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROBLAST; FEMALE; FOLLICULAR LYMPHOMA; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; KARYOTYPE; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG CARCINOMA; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 84864275780     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPZRRL2DGC2ODA     Document Type: Article

References (23)

1. Arber DA, Vardiman JW, Brunning RD, et al. Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:116-117.
2. Testoni N, Borsaru G, Martinelli G, et al. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features. Haematologica. 1999;84:690-694. (Pubitemid 29424403)
3. Weisser M, Haferlach C, Haferlach T, et al. Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3)(q21;q26) positive AML. Leuk Lymphoma. 2007;48:2145-2151. (Pubitemid 350107691)
4. Lo Coco F, Pisegna S, Diverio D. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica. 1997;82:364-370. (Pubitemid 28023324)
5. Mitani K, Ogawa S, Tanaka T, et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 1994;13:504-510.
6. Motomura S, Fujisawa S, Tsunooka S, et al. Translocation (3;21)(q26;q22) in de novo acute myelogenous leukemia. Leukemia. 1997;11:172-173. (Pubitemid 27065068)
7. Nucifora G, Begy CR, Erickson P, et al. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad Sci U S A. 1993;90:7784-7788. (Pubitemid 23250035)
8. Nucifora G, Begy CR, Kobayashi H, et al. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci U S A. 1994;91:4004-4008. (Pubitemid 24139561)
9. Chen Z, Morgan R, Baer MR, et al. Translocation (3;21) characterizes crises in myeloid stem cell disorders. Cancer Genet Cytogenet. 1991;57:153-159.
10. Pedersen-Bjergaard J, Johansson B, Philip P. Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation. Cancer Genet Cytogenet. 1994;76:50-55.
11. Cui W, Sun J, Cotta CV, et al. Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. Am J Clin Pathol. 2011;136:282-288.
12. Onciu M, Schlette E, Medeiros LJ, et al. Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. Am J Clin Pathol. 2001;116:886-892. (Pubitemid 33108160)
13. Shaffer LG, Slovak ML, Campbell LJ, eds. ISCN: An International System for Human Cytogenetic Nomenclature (2009). Basel, Switzerland: Karger; 2009.
14. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood. 1990;76:1214-1219. (Pubitemid 20318167)
15. Lin P, Jones D, Medeiros LJ, et al. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol. 2006;126:530-533. (Pubitemid 44498502)
16. Mitelman F, Johansson B, Mertens F, eds. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (2011). Available at http://cgap.nci.nih. gov/Chromosomes/Mitelman. Accessed June 7, 2011.
17. Goyama S, Kurokawa M. Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci. 2009;100:990-995.
18. Mitani K. Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene. 2004;23:4263-4269. (Pubitemid 38758593)
19. Yin CC, Cortes J, Barkoh B, et al. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer. 2006;106:1730-1738.
20. Lugthart S, Groschel S, Beverloo HB, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010;28:3890-3898.
21. Leone G, Fianchi L, Voso MT. Therapy-related myeloid neoplasms. Curr Opin Oncol. 2011;23:672-680.
22. Vardiman JW, Arber DA, Brunning RD, et al. Therapy-related myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:127-129.
23. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16:198-204.